Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Sanofi’s reportedly on the verge of ‘sizable’ job cuts as diabetes business sputters

Damian Garde French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer ...

Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

Valeant cuts ties with shadowy pharmacy Philidor

Carly Helfand Valeant is severing all ties with specialty pharmacy Philidor–which a short seller recently claimed it used to inflate its top line–after reports that Philidor ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

Novartis CEO eyes more cost cuts to satisfy margin demands

Tracy Staton Novartis execs are rolling up their sleeves for another round of cost cuts. "Very significant" cost cuts, CEO Joe Jimenez tells the Financial Times, partly from ...

Synta cuts another 20% of staff and rallies around its cancer drug

Damian Garde Synta Pharmaceuticals is again slashing its payroll, cutting costs across the board as it presses ahead with ganetespib, a long-delayed cancer treatment. FierceBiotech ...

Here’s a first: Regeneron cuts forecast after hard-charging Eylea sales miss

Carly Helfand Here's something Regeneron isn't used to: Cutting sales forecasts for blockbuster eye drug Eylea. But that's just what the New York biotech did Tuesday amid ...

Impax cuts nearly 50 employees to save money

Eric Palmer Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D ...

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

Nick Paul Taylor In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of ...

Cabozantinib flops against prostate cancer, forcing big jobs cuts at Exelixis

John Carroll FierceBiotech News

Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant

Carly Helfand Allergan's pulled back the veil on the restructuring it's hoping will lure shareholders away from Valeant's $ 53 billion hostile buyout bid. Among the blueprints: ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS